International audienceDyskinesia is a major side-effect of chronic l-DOPA administration, the reference treatment for Parkinson's disease. High-frequency stimulation of the subthalamic nucleus (STN-HFS) alleviates parkinsonian motor symptoms and indirectly improves dyskinesia by decreasing the L-DOPA requirement. However, inappropriate stimulation can also trigger dyskinetic movements, in both human and rodents. We investigated whether STN-HFS-evoked forelimb dyskinesia involved changes in glutamatergic neurotransmission as previously reported for L-DOPA-induced dyskinesias, focusing on the role of NR2B-containing N-methyl-D-aspartate receptors (NR2B/NMDARs). We applied STN-HFS in normal rats at intensities above and below the threshold for...
Deep-brain stimulation of the subthalamic nucleus appears to reduce levodopa-induced dyskinesias, bu...
International audienceThis study examined the cellular changes produced in the striatum by chronic L...
Evidence for in vivo involvement of striatal D1 receptors in levodopa-induced dyskinesia has been pr...
International audienceDyskinesia is a major side-effect of chronic l-DOPA administration, the refere...
International audienceDyskinesia is a major side effect of chronic levodopa (L-DOPA) administration,...
International audienceThe neurobiological mechanisms by which high-frequency stimulation of the subt...
La stimulation à haute fréquence (SHF) du noyau subthalamique (NST) joue un rôle essentiel chez les ...
Dyskinesias represent a major complication of dopamine replacement therapy in Parkinson's disease (P...
L-DOPA is the most effective treatment for Parkinson’s disease (PD), but prolonged use leads to disa...
High frequency stimulation (HFS) of the subthalamic nucleus (STN) treats the totality of Parkinson's...
Hyperactivity of striatal glutamatergic synaptic transmission in response to dopamine depletion play...
Levodopa (L-DOPA)-induced dyskinesias represent the main side effect of the therapeutic strategy cli...
Abnormal function of NMDA receptor has been suggested to be correlated with the pathogenesis of Park...
Deep-brain stimulation of the subthalamic nucleus appears to reduce levodopa-induced dyskinesias, bu...
International audienceThis study examined the cellular changes produced in the striatum by chronic L...
Evidence for in vivo involvement of striatal D1 receptors in levodopa-induced dyskinesia has been pr...
International audienceDyskinesia is a major side-effect of chronic l-DOPA administration, the refere...
International audienceDyskinesia is a major side effect of chronic levodopa (L-DOPA) administration,...
International audienceThe neurobiological mechanisms by which high-frequency stimulation of the subt...
La stimulation à haute fréquence (SHF) du noyau subthalamique (NST) joue un rôle essentiel chez les ...
Dyskinesias represent a major complication of dopamine replacement therapy in Parkinson's disease (P...
L-DOPA is the most effective treatment for Parkinson’s disease (PD), but prolonged use leads to disa...
High frequency stimulation (HFS) of the subthalamic nucleus (STN) treats the totality of Parkinson's...
Hyperactivity of striatal glutamatergic synaptic transmission in response to dopamine depletion play...
Levodopa (L-DOPA)-induced dyskinesias represent the main side effect of the therapeutic strategy cli...
Abnormal function of NMDA receptor has been suggested to be correlated with the pathogenesis of Park...
Deep-brain stimulation of the subthalamic nucleus appears to reduce levodopa-induced dyskinesias, bu...
International audienceThis study examined the cellular changes produced in the striatum by chronic L...
Evidence for in vivo involvement of striatal D1 receptors in levodopa-induced dyskinesia has been pr...